Status:

WITHDRAWN

Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation

Lead Sponsor:

Aurobindo Pharma Ltd

Conditions:

Bronchial Asthma

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

Pharmacodynamic bioequivalence study of Albuterol Sulfate Inhalation Aerosol 0.09 mg

Detailed Description

To assess the pharmacodynamic bioequivalence of Albuterol Sulfate Inhalation Aerosol 0.09 mg base/ INH \[Aurobindo Pharma, USA, Inc\] compared to authorized generic drug Albuterol Sulfate HFA Inhalati...

Eligibility Criteria

Inclusion

  • Male and non-pregnant female subjects (18-65 years of age).
  • Stable mild asthmatics based on National Asthma Education and Prevention Program (NAEPP) guidelines.
  • FEV1 ≥ 80% of predicted.
  • Airway responsiveness to methacholine demonstrated by a pre-albuterol dose (baseline) PC20 ≤ 8 mg/mL or equivalent PD20.
  • Nonsmokers for at least six months prior to the study and a maximum smoking history of five pack-years (the equivalent of one pack per day for five years).
  • Written informed consent.

Exclusion

  • Evidence of upper or lower respiratory tract infection (e.g., pneumonia, bronchitis, sinusitis) within six weeks prior to the study.
  • History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season.
  • History of cystic fibrosis, bronchiectasis or other respiratory diseases.
  • History of cardiovascular, renal, neurologic, liver or endocrine dysfunction, including ECG with evidence of ischemic heart disease.
  • Treatment in an emergency room or hospitalization for acute asthmatic symptoms or need for daily oral corticosteroids within past three months.
  • Known intolerance or hypersensitivity to any component of the albuterol MDI

Key Trial Info

Start Date :

April 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05292976

Start Date

April 1 2022

End Date

December 1 2022

Last Update

May 20 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Investigational site #1

San Jose, California, United States, 95117

Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation | DecenTrialz